Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer

BACKGROUND. Early discontinuation of aromatase inhibitors (AIs) is common and leads to poor outcomes but is challenging to predict. In the Exemestane and Letrozole Pharmacogenetics trial, a high rate of early discontinuation due to intolerance was observed. We hypothesized that early changes in pati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Kadakia, Kunal C., Snyder, Claire F., Kidwell, Kelley M., Seewald, Nicholas J., Flockhart, David A., Skaar, Todd C., Desta, Zereunesay, Rae, James M., Otte, Julie L., Carpenter, Janet S., Storniolo, Anna M., Hayes, Daniel F., Stearns, Vered, Henry, N. Lynn
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2016
Matèries:
Breast Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861358/
https://ncbi.nlm.nih.gov/pubmed/27009936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0349
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars